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ABSTRACT. Transgenic animals are used extensively in the study of in 
vivo gene function, as models for human diseases and in the production 
of biopharmaceuticals. The technology behind obtaining these animals 
involves molecular biology techniques, cell culture and embryo manipu-
lation; the mouse is the species most widely used as an experimental 
model. In scientific research, diverse models are available as tools for the 
elucidation of gene function, such as transgenic animals, knockout and 
conditional knockout animals, knock-in animals, humanized animals, 
and knockdown animals. We examined the evolution of the science for 
the development of these animals, as well as the techniques currently 
used in obtaining these animal models. We review the phenotypic tech-
niques used for elucidation of alterations caused by genetic modifica-
tion. We also investigated the role of genetically modified animals in the 
biotechnology industry, where they promise a revolution in obtaining 
heterologous proteins through natural secretions, such as milk, increas-
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ing the scale of production and facilitating purification, thereby lowering 
the cost of production of hormones, growth factors and enzymes.
Key words: Transgenic animals; Knockout animals; Biotechnology; 
Disease models
INTRODUCTION
Science has advanced through observation and experimentation. So has the evolution 
of biotechnology. The emergence of animal models through genetic manipulation has greatly 
helped the development of scientific and biomedical knowledge. To speak of genetically modi-
fied animals is to focus on a very important chapter in the history of the science of laboratory 
animals, in which the function of genes was first identified in living individuals. Based on this 
knowledge, new ideas for treatment of genetic diseases and other diseases have emerged; these 
tend to revolutionize classic medicine, bringing benefits not only to man but to all living things.
Here we give a brief history of biotechnology and the production of genetically modi-
fied animals, as well as the types of animals that can be created, and findings derived from 
recombinant DNA technology and gene targeting.
SOME HISTORICAL ASPECTS
After 150 years of research, science has progressed from uncovering the principles 
of heredity to mimicking biological events in the laboratory. This information has provided 
significant advances in medicine over the last century, creating a new branch of industry, the 
billion-dollar biotechnology industry.
Since the initial genetic studies of Gregor Mendel in 1865, numerous researchers have 
contributed to the understanding and consolidation of his idea, which until then was only 
promising. In these decades of studies, important events took place, such as the discovery 
of the relationship of DNA with the transmission of genetic traits, the characterization of its 
chemical structure and of its three-dimensional structure, methodology to produce recombi-
nant DNA, DNA cloning and sequencing, new animal models with random and, later, directed 
mutations, allowing the production of the first transgenic mice.
DEVELOPMENT OF GENETICALLY MODIFIED ANIMAL MODELS
At the beginning of the 20th century, with the appearance of the first genetic studies 
involving animal models, it was found that interference in the exchange of genetic information 
between different animals of the same species is important. Phenotypic characteristics that 
were found in these mating programs resulted in hypotheses of inheritable mechanisms that 
could behave differently over the generations, depending on the dominance and penetrance of 
these characteristics in individuals. 
These observations showed the importance of the animal model in phenotype studies 
and encouraged the creation of new models that could respond to various biological questions. 
Through planned mating, diverse models appeared, including isogenic blood-relative models 
that could be used in a multitude of studies with little variability in the results. Over time, mu-
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tant animals appeared spontaneously in production colonies, differing from their parents and 
able to pass on these differences to their offspring. Other strains appeared from these sponta-
neous mutations and other models arose. 
The possibility of enrichment of the animal models due to genetic alterations was 
evident. Contemporary researchers in the mid-20th century pursued various approaches to 
increase the possibility of genetic alterations in existing animal models and thus create new 
models. Chemical agents, such as base analogues, intercalating agents and agents reactive 
to DNA (ethyl methanesulfonate, methyl methane sulfate, methyl N-nitrosourea, and ethyl 
N-nitrosourea) and also physical agents, such as radioactivity, were and still are widely used 
to produce forced random mutations in the animal genomes. Animals with phenotypic differ-
ences were then separated and their genomes completely analyzed to determine the genetic 
modifications involved with the phenotypic changes that were observed.
Taking a parallel path, Rudolf Jaenisch (1976) published the first report of introduc-
tion of an exogenous DNA virus (SV40) into mouse embryos, opening the door to the possibil-
ity of performing genetic alterations that were no longer random, but directed with the use of 
specific, chosen gene alterations. 
Gordon and Ruddle (1981) reported the birth of a mouse that had been genetically 
modified through microinjection of purified DNA into single-cell mouse embryos. This meth-
odology marked the birth of transgenesis and controlled genetic alteration in animal models. 
Thereafter, the growth in the production of genetically modified animal models by transgen-
esis has not stopped, and consequently the systemic knowledge of organisms and diseases has 
progressed with a speed unparalleled in history.
TECHNIQUES FOR THE MANAGED CREATION OF GENETICALLY 
MODIFIED ANIMAL MODELS 
To create embryos in which the genome is permanently altered and the transfected 
DNA is permanently and irreversibly incorporated into the genetic material of the host cells, 
there are at least three important steps to be surmounted: 1) to produce a gene construct in 
vitro that is functional in accordance with the hypothesis of the proposed study; 2) to cause the 
required DNA to cross the plasma membrane, the cytoplasm and reach the nucleus, and 3) to 
cause the exogenous DNA to be integrated into the genome of the host cell and to be passed 
on unaltered to the following generations.
 
Gene construct 
A gene construct can vary in complexity according to the insertion of interest. 
The construct can be designed to be inserted randomly into the genome of the animal, 
which is called transgenesis by addition, or can be designed to be inserted into the ge-
nome at a specific targeted site, into the correct position of a determined chromosome, 
which is called transgenesis by homologous recombination. In both cases, the construct 
must be impeccable, with structures to control gene expression, such as: a promoter, a 
site of transcription initiation, a site of polyadenylation, and a site of transcription ter-
mination. That is, the information that is being inserted into the receptor genome has a 
beginning, a middle, and an end, thus avoiding problems of uncontrolled expression in 
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the host cell. In order to accomplish the objectives of the proposed genetic modification 
studies, a large variety of machinery is available today to control the expression of trans-
genes in a ubiquitous or conditional manner.
Insertion of the DNA of interest into cells
A variety of strategies can be used to cause exogenous DNA to penetrate the host cell. 
Calcium precipitation. This is the original method described by Graham and Van 
der Eb (1973), in which the DNA is precipitated with calcium salts. The precipitated mate-
rial is incorporated into endosomes, released into the cytoplasm and subsequently enters the 
nucleus. This method is fairly simple but very inefficient, mainly because much of the DNA 
is degraded within the endosome; however, it does succeed in some types of cell cultures.
Electroporation. This technique, described by Neumann et al. (1982), revolution-
ized the methodology of transfection of nucleic acids into cells in culture. The cells are 
mixed with DNA in solution and subjected to a sudden, powerful electric current, which 
causes the pores in the plasma membrane to open, allowing entry of the DNA. This is 
probably the most efficient physical method and can be applied to most cell types, it is 
also widely used.
Lipid micelles. Also known as lipoplexes, this methodology is based on the forma-
tion of complexes involving cationic lipid molecules of DNA. In addition to facilitating 
the passage of the genetic material through the cell membrane, it protects against the ac-
tion of nucleases. It is one of the most popular and simple methods, requires no special 
equipment, is applicable to most cell types, but it is less efficient than electroporation.
Microinjection. This is the most widely used method in transgenesis for gene addi-
tion. In this method, the DNA in solution is physically injected into the cell nucleus. This 
method is considered 100% efficient to carry the DNA into the nucleus of somatic cells, but 
it has some disadvantages; it requires specialized equipment and highly skilled individuals, 
trained to perform the microinjection (Capecchi, 1980). This technique is widely used for 
insertion of gene vectors into fertilized oocytes, and it has a success rate of 4-8% of ani-
mals born with the transgene integrated into the genome (Brinster et al., 1985).
Viral vectors. This is the most recently employed method; it consists of the inte-
gration of the DNA of interest into the genome of a virus that is used to infect the cell. 
Among the viruses used are Simian virus 40 (SV40), retroviruses and lentiviruses. This 
method gives high rates of efficiency of expression (Hofmann et al., 2003).
Integration
Integration of exogenic DNA into the host genome occurs with extremely low 
efficiency, except in cases where the DNA to be transferred is contained in the viral 
particle (Hofmann et al., 2003). It is believed that the integration of exogenic DNA 
into the genome of the host cell occurs as a consequence of errors made when the DNA 
repair machinery of the host cell accidentally incorporates the exogenous molecule in 
an attempt to repair breaks in the double-stranded DNA that occasionally occur in cells 
(Brinster et al., 1985).
Without the use of viruses, the integration event is so rare that in cells that are success-
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fully transfected only a single event takes place; thus, the expression levels that are obtained 
are mostly a consequence of the locus of integration than directly to the number of copies 
inserted (Henikoff, 1998).
Due to the random nature of DNA breakage, integration of transfected DNA 
typically also occurs in random locations in the genome. Incorporated exogenous DNA 
could potentially disrupt, prevent or impede the expression of a gene of the host, al-
though this probability is also rare. More frequently, the DNA integrates into a tran-
scriptionally inactive region of the genome. Therefore, incorporation of DNA into the 
genome does not guarantee its expression. Even when expression occurs, it can often 
be unstable, gradually decrease over time, or sometimes express itself, or not, in an 
unforeseen way (Wilkie et al., 1986).
Due to these phenomena, it appears that only a fraction of the cells that integrate the 
exogenous DNA express the transgene, resulting in a mosaic pattern of expression. Positive 
selection techniques are used for the identification of cells positive for integration. 
The predominant method of positive selection is through association of the gene of 
interest with a selection gene, for example, one that protects the cell from a toxic agent. The 
agent most often used for this purpose is a derivative of neomycin, called G418, which is 
added to the cell culture medium and inhibits cell growth. The cells that grow have the resis-
tance gene NeoR integrated into the genome, which was inserted into the vector along with the 
transgene (Santerre et al., 1984).
VECTOR CREATION 
Called a transgenesis vector, this structure is composed of nucleic acid, usually DNA, 
which is manipulated using molecular biology techniques. Vectors are derived from viruses 
and prokaryotic or eukaryotic plasmids that have the function of carrying the gene of interest 
into the host cell nucleus and integrating it into the genome.
Due to the complexity of gene regulation in animals, the best option is the use of the 
coding sequence of the gene, or cDNA containing the start codon (ATG), the complement of 
the mRNA of interest, thereby avoiding the requirement for post-transcription processing, 
splicing. For this coding sequence of the protein of interest to be efficiently expressed in mam-
malian cells, the following should be combined in the construct:
i) Promoter + upstream regulatory sequences - the combination of both is usually 
called “promoter”. This region will determine the conditions of exogenous gene expression, as 
well as its intensity and location. Promoters may also be inducible, their activation mediated 
by drugs or by the physiological state of the animal.
ii) Coding sequence, which contains the genetic information for the messenger RNA 
(mRNA) to be formed. It is essential that there is an initiation codon (ATG) and a stop codon 
(TAA, TGA, TAG) in this sequence, which will signal the codons to be read in translation of 
mRNA by the ribosomal RNA (rRNA), resulting in the amino acid chain of the protein.
iii) Termination/polyA signaling sequence. The stop codon does not result in ami-
no acids in the translation, acting as the stop signal of the process; the sequences TAG, 
TAA or TGA are used for this. The polyadenylation sequence triggers the addition of a 
repetition of adenosine at the end of the mRNA, providing stability to the molecule and 
allowing its translation.
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TYPES OF GENETICALLY MODIFIED ANIMALS AND HOW THEY ARE 
PRODUCED
Transgenic animals  
Transgenic animals are those in which an exogenous gene was artificially inserted and 
stably incorporated into the genome of every cell of the organism and that can be transmitted 
to their descendants. The first transgenic mouse had the genome sequence of the Maloney 
leukemia virus inserted into its genome (Jaenisch, 1976).
The best way to get all the cells that compose the organism to express the exogenous 
gene is to insert it into cells that give rise to other cell types, i.e., the fertilized egg cell. In 
simple terms, the creation of transgenic animals begins with proper construction of the gene 
of interest and its transfection to the fertilized egg cell.
Many animal species have been genetically modified, including fish (Ozato et al., 
1986), frogs (Ishibashi et al., 2008), rats (Agca et al., 2008), mice (Gordon and Ruddle, 1981; 
Joyner and Sedivy, 2000), cattle (Bondioli et al., 1991), birds (Etches and Verrinder Gibbins, 
1997), and pigs (Kragh et al., 2009). The protocols to obtain such animals are diverse, but all 
consist of random integration of the exogenous gene into the genome of the animal. In most 
mammals, the exogenous DNA is inserted by pronuclear microinjection.
In mice, the most commonly used model, the frequency with which the exogenous DNA 
is incorporated into the genome is satisfactory in the case of the egg cell, a totipotent cell with a 
high capacity for cell division. Certain strains possess egg cells with larger pronuclei, providing 
a greater ease of microinjection. An example is the use of oocytes derived from FVB animals.
The animal generated from this egg cell, known as a transgenic founder, is heterozy-
gous for the transgene, i.e., one of the chromosomes has incorporated the transgenic DNA, but 
not the homologous chromosome. Consequently, only half of the animals obtained from the 
F1 mating will also be heterozygous.
Transgenic models have diverse functions in research, in which the inserted gene may 
have its effects evaluated in vivo during the developmental stages, as in the evolution of dis-
eases, in studies of mutations, in the search for therapies, and other parameters that necessitate 
an animal model for study. Industrially, the transgenic model can be used to obtain commer-
cial productivity characteristics, and disease resistance, and can be used as a bioreactor in the 
production of biopharmaceuticals.
Knockout animals
The great contribution of these models was in the study of gene function through the 
phenotype presented due to the effect of allelic deletion. Until very recently, the only way to 
do this was to look for animals or humans suffering from hereditary diseases. In the case of 
animals, the incidence of such diseases could be increased by using mutagenic chemicals or 
irradiation, then the location of the mutation was mapped and the defective gene cloned.
Unlike the transgenic model produced by the addition of random exogenous DNA, 
the knockout model is obtained by targeted insertion. This targeted integration is performed 
through the mechanism of homologous recombination and has an extremely low success rate 
(Gama Sosa et al., 2010). 
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Homologous recombination is a separate chapter in the methodology for obtaining 
knockout animals. This technique allows the insertion of a determined transgene into a spe-
cific locus, causing it to locate exactly in the desired portion of the chromosome. The most 
common way to delete exons is through the creation of a targeted construct, also called 
“targeted”. In this case, the plasmid must contain a homologous portion of the start of the 
gene, known as “left arm” and a portion obtained along the gene, or even the final portion, 
called the “right arm” (Capechi, 1980).
Between these portions, an exon must be situated that is important for the functionality 
of the protein. These homologous regions will pair with the corresponding sequences in the gene 
of interest. The longer the arms, the greater the probability that the pairing will occur. In practice, 
the combined length of both arms is between 6 and 10 kb (Joyner and Sedivy, 2000). As a result 
of this pairing and a double recombination, one in each arm, the original gene, or “wild type” is 
replaced by the transgene contained between the two arms of the construct. The gene sequence 
to be introduced may contain another gene, usually a reference sequence of a positive selection 
gene, thus generating substitution of expression of the original gene for NeoR. 
Due to the low efficiency of the occurrence of two recombinations so close together, 
the strategy of performing this process in cell culture is used; but for these cells to give rise in 
the future to a complete organism they need to be pluripotent cells. The ideal cells are known 
as ES cells (embryonic stem) (Smithies et al., 1985; Notarianni and Evans, 2006). It was found 
that these cells called “germ lines” were perfectly suited for targeted insertion and could be 
identified through mechanisms of positive and negative selection. Currently, protocols for the 
cultivation and maintenance of these cells exist for only a few species (Grivennikov, 2008).
ES cells can be transferred by micromanipulation into the interior of murine embryos 
at about three to four days of age, during the blastocyst pre-implantation phase. These modi-
fied cells will attach to the normal cells of the inner cell mass of the blastocyst and will behave 
as cells of the embryo itself, participating in the formation of the three germ layers of the in-
dividual (ectoderm, mesoderm and endoderm) and contributing to the formation of all tissues 
of the adult mouse. This creates what is known as a chimeric mouse, in which each organ is 
formed from both cells of the embryo itself and from the ES-injected cells, which will include 
the gonads, giving rise to germ line animals (Gama Sosa et al., 2010). 
At present, strains of knockout mice for 10% of the genes have been produced, and 
ambitious projects like the KOMP (Knock-Out Mouse Project) and the EUCOMM (European 
Conditional Mouse Mutagenesis) aim to obtain strains with individual deletions for all genes, 
as well as mutations known to be related to syndromes.
Conditional knockout animals
Deletion of genes essential for development can result in embryonic lethality, due to 
lack of influence of this gene in the embryogenesis of the animal; thus, mice die in the uterus, 
making it difficult to study events that occur after birth, and impossible to study the function 
of these genes in adult animals. Fortunately there are strategies, which are now becoming 
prevalent, to circumvent this problem, aiming to avoid problems with embryonic lethality 
(Gama Sosa et al., 2010).
One possible strategy is the use of the conditional deletion system, which involves 
gene deletion under specific conditions. The main strategy is known as the Cre-Lox system. 
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The Cre enzyme is a 38-kDa recombinase, present in the P1 bacteriophage, which mediates 
recombination of DNA regions flanked by sequences such as loxP (Hamilton and Abremski, 
1984). The loxP sequence has 34 bp with a defined orientation. When the loxP flanks are in 
consensus, the region contained between them is excised, leaving a single loxP sequence. 
When the flanking sites are in opposite positions, the Cre enzyme recombines the contained 
region, reversing it. That is, animals with a targeted insertion in the same position as the loxP 
flanks are obtained by means of homologous recombination in ES cells. This insertion gene 
may be the same gene present in the locus, but now flanked by the loxP sequence. The situ-
ation that will permit its normally conditional expression is expression of Cre recombinase, 
which may be ubiquitous or conditioned to a determined organ or cell type, and eliminates the 
flanked gene. This Cre recombinase gene can be inherited from another transgenic animal and 
will allow conditional expression of this protein.
This conditional control is based on the Cre enzyme, which may have its expression 
controlled through the promoter related to it. The promoter that regulates the expression of the 
Cre gene will control the pattern of deletion of the target gene. This promoter may be specific 
to cell types, the physiological state of the animal or inducible by drugs.
i) Cell-specific promoter. The regulatory region of the Cre gene is important in deter-
mining the cell or group of cells that express the recombinase. Using the aP2 promoter, it is 
possible to delete the gene of interest only in adipocytes, the αMHC promoter for deletion in 
cardiomyocytes, the ALB promoter for hepatic cells, the Nestin promoter for neurons, the K5 
promoter for epithelial cells of the skin, the CD19 promoter for B lymphocytes, and the Cola1 
promoter for osteoblasts. 
ii) Temporal promoters. Regulatory sequences that promote gene expression at spe-
cific periods or physiological states. The CaMKII promoter can be used for gene deletion in 
neurons only after birth. 
iii) Inducible promoters. Regulatory sequences that are activated or deactivated by 
exogenous molecules. The TET system of induction, based on the TET operon system of 
Escherichia coli, is the most widely used (Sun et al., 2007). With this strategy, the Cre enzyme 
can be expressed, and consequently delete the gene at a specific time according to the research 
objective. To accomplish this, tet-Cre animals are crossed with loxP animals, and after mating 
of homozygous flanked animals, tetracycline or its analogue, doxycycline, is administered, 
excising the gene of interest and obtaining the desired knockout at the targeted systemic site, 
at the determined time of development of the animal.
Knock-in animals
As described, these techniques are most frequently used to introduce genes into ran-
dom locations (transgenics) or to delete specific portions of genes (targeted knockout). The 
same techniques can be used to introduce new genetic elements into specific sites, known as 
knock-in (Haruyama et al., 2009). One application of this technique is to study the expression 
of molecules, identifying cells that express and modulate expression, using reporter molecules 
for this. The most commonly used reporter is the enzyme β-galactosidase, which can be de-
tected with a variety of colored substrates, and the “green fluorescent protein”, also known as 
GFP (Welsh and Kay, 1997). 
For this, after the stop codon sequence of the studied gene, an entry site within the ri-
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bosome is added, termed IRES (internal ribosome entry site), followed by the cDNA sequence 
of the reporter gene. The IRES sequence has the property of permitting a single molecule of 
eukaryotic mRNA to code for two different proteins.
Knock-in animals are also fundamental models in other studies. Through targeted 
insertion the wild sequence of a targeted gene can be modified to a mutated sequence, related 
to disorders and other syndromes (Davis et al., 2007; Desbonnet et al., 2009).
A very interesting technical use of knock-in is the insertion of a target gene into the 
locus of another gene, substituting it. Some genes belong to a large family, but the members 
display individual characteristics, which often preclude compensation. Zheng-Fischhöfer et 
al. (2006), in an attempt to avoid embryonic lethality in knockout animals for the Cx43 gene, 
substituted the loci deleted with the Cx31 gene, producing the knock-in animal Cx4331/31. The 
authors perceived that despite the relative gene homology, the restoration of cell communica-
tion via Cx31 was not sufficient for normal development of the heart, showing selectivity of 
size and electrical charge between proteins Cx43 and Cx31.
Mice that host fragments of chromosomes 
Technologies developed in recent decades have made possible the manipulation of 
artificial chromosomes such as PACs, YACs and BACs, allowing the use of sequences with 
hundreds of kilobases originating from human genomes, those of mice and many other species 
for animal transgenesis (Sparwasser and Eberl, 2007).
The first mouse genetically modified by BACs was obtained by Yang et al. (1997); 
it allowed mapping the expression of various genes through co-expression of reporter genes. 
Later studies optimized the technique by integrating it with other methods of transgenesis.
During the 1990s, many experiments were conducted using artificial chromosomes, 
in order to obtain mice genetically modified with human genes (Sparwasser and Eberl, 2007). 
This humanized mouse is useful for the study of the expression of factors related to the im-
mune system, identification of genes related to human diseases and the creation of new disease 
models (Kazuki et al., 2003; Li et al., 2009).
One important use of these animals would be the ability to produce human antibod-
ies that could be injected into patients without the possibility of being recognized, or even 
destroyed, by the immune system of the individual. Such antibodies could be used to rapidly 
provide protection against dangerous pathogens, or be directed against critical surface mol-
ecules of T cells to act as immunosuppressive agents during organ transplants.
Knockdown mice using RNA interference technology 
The knockdown of genes, either in a constitutive or a conditional manner, is performed 
using RNA interference (RNAi) techniques. The first steps for understanding the RNAi tech-
nique came from data from invertebrate studies. Long molecules of double-stranded RNA 
(dsRNA) were seen to be processed into small interfering RNAs (siRNAs) by the ribonucle-
ase, Dicer. The antisense siRNA served as a standard for the complex called RISC (RNA-
induced silencing complex), which recognizes and cleaves the complementary mRNA, which 
consequently is rapidly degraded (Fire et al., 1998). In mammals, dsRNAs longer than 30 
bp provoke a global response of inhibition of protein synthesis and non-specific degradation 
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of mRNA. However, small synthetic molecules of dsRNAs can serve as triggers for specific 
breaks of mRNAs in animal cells.
The strategy for production of a knockdown animal for a particular gene begins with 
the design of the vector. The vector must contain a sequence that encodes an RNA transcript 
complementary to the target mRNA and must contain a hairpin region, forming an shRNA, a 
key feature for processing by the Dicer enzyme and subsequent formation of siRNA (Hitz et 
al., 2009). The vector should be integrated into the genome so that the knockdown is perma-
nent and is transmitted through generations. 
The big difference between the knockdown and the knockout model is the type of de-
letion caused. Knockout animals have the sequence responsible for mRNA production deleted 
from the genome, while in the knockdown animals, the interference process acts during the 
post-transcriptional phase. This characteristic ensures that the target protein is completely ab-
sent in the knockout animals, while in the knockdown model that efficiency is lower, achiev-
ing up to a 90% decrease in protein quantity (Hitz et al., 2009).
In some cases, permanent knockdown of the target protein is not required because 
of malformation of the animal or even for the understanding of gene function. In such cases, 
we can associate the expression of RNAi with an inducible promoter controlled by doxycy-
cline (Tet-On inducible expression system), thus obtaining the knockdown for specific periods 
(Dickins et al., 2007).
USE OF GENETICALLY MODIFIED ANIMALS IN SCIENTIFIC RESEARCH
At the beginning of the last century, the science of genetics was still in formation, but 
animals were already domesticated, bred and genetically selected in animal facilities for use in 
research on anatomy, physiology, reproduction, and immunology. Recently, humanity has gone 
through an era of controversy, because, at the same time that scientists say that it is essential to 
use live animals for experimentation, diverse groups say they are opposed to their use. The fact 
is that in vitro models equivalent to animal models currently do not exist. The complexity of a 
living creature cannot be mimicked in vitro, and therefore there is a consensus among scientists 
that the use of these animals is ethical. Among the animal species, the mouse is considered 
to be the best model for studying human diseases and therefore the one most employed. This 
choice is based on characteristics such as: small size, short life cycle, the possibility of genomic 
manipulation, many molecular and physiological similarities with humans, human orthologues 
mapped, and the complete genome sequenced (Rosenthal and Brown, 2007).
Until the 1970s, the only way to study genetic diseases was with the identification of 
animals with spontaneous mutations that showed phenotypic changes similar to a disease in 
humans. With the advance of genetic engineering, it was no longer necessary to wait; these 
animals could be produced with the desired alterations, since the genetic causes of the disease 
in question were known. So, animals were produced that serve as models for studies of differ-
ent types of cancers (Santos et al., 2008), heart disease (Moon, 2008), hypertension (Zadelaar 
et al., 2007), diabetes (Leroith and Gavrilova, 2006), obesity (Blüher, 2005), osteoporosis 
(Klein, 2008), glaucoma (Zhou et al., 2008), blindness (Moussaif et al., 2006), deafness (Lei-
bovici et al., 2008), Huntington’s syndrome (Heng et al., 2008), Down’s syndrome (Patterson, 
2009), Parkinson’s disease (Harvey et al., 2008), Alzheimer’s disease (Gotz et al., 2009), anxi-
ety (Kalueff et al., 2007), and depression (Kalueff et al., 2007). 
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After deciphering the sequence of nucleotides that compose the genomes of humans, 
mice and other species, the challenge for researchers is understanding the genes and their 
functions, interactions, expression patterns, and their correlation with diseases and syndromes. 
Without doubt, the models discussed here will be vital in these processes, i.e., knock-in, con-
stitutive knockout, conditional knockout, or knockdown animals.
After the creation of the model, the next step is a more complex, time-consuming and 
practically unlimited process, phenotyping. Phenotyping can be divided into three steps: 
1 - Clinical and morphological characterization. Evaluation of all parameters related 
to normal functioning of the organism as well as morphological characteristics, such as: heart 
rate, respiratory rate, blood pressure, behavioral analysis, histological and organ analysis, au-
ditory and ophthalmic analysis, monitoring of growth and development of the animal, profile 
of serum molecules, immune and reproductive systems. 
2 - Molecular characterization. This process will principally evaluate three types of 
molecules: DNA, mRNA and proteins, all related to the mechanism of transgenesis. In some 
models, it is essential to identify the region of integration of the vector into the genome of 
the animal, as well as the number of copies inserted, which can be accomplished using in situ 
hybridization. The qPCR technique is used to evaluate the pattern and level of expression of 
mRNA in cells. Western blot, ELISA or radioimmunoassay techniques are used to evaluate the 
levels of proteins produced, while immunohistochemistry is employed to analyze the location 
and proper functionality of the proteins.
3 - Pathological characterization. This step will study the possibilities of participation 
of the altered gene in the spontaneous onset of disease or ease of onset during their induction. 
Examples of diseases include cancer, diabetes, hypertension, cardiac problems, renal prob-
lems, anemia, autoimmune diseases, and allergies.
USE OF GENETICALLY MODIFIED ANIMALS IN THE PRODUCTION OF 
BIOPHARMACEUTICALS
The production of high-value pharmaceutical substances, including recombinant pro-
teins, has a value of billions of dollars per year around the world; in this context, genetically 
modified animals promise to revolutionize the pharmaceutical industry. The heterologous pro-
teins produced in bioreactors are normally hormones, growth factors and enzyme complexes. 
Transgenic animals are indicated as potential bioreactors for the synthesis of heterologous pro-
tein complexes. They are capable of post-translational modifications, such as glycosylations, 
in a similar way to what occurs naturally in humans, more reliably than other systems, such as 
yeast. Many fluids have been tested, such as blood, urine, seminal plasma, egg white, and milk.
The mammary gland can be considered the most natural and efficient producer of 
heterologous proteins. Many studies have demonstrated that recombinant proteins can be pro-
duced in milk, including human IGF-1 (Zinovieva et al., 1998), hGH (Devinoy et al., 1994), 
human lysozyme (Lee et al., 1998), human lactoferrin (Platenburg et al., 1994), human eryth-
ropoietin (Sohn et al., 1999), human parathyroid hormone (Rokkones et al., 1995), and coagu-
lation factor VIII (Chrenek et al., 2007).
Mammals that serve as bioreactors are genetically modified to produce the heterolo-
gous protein exclusively in the mammary gland, optimizing its production and avoiding del-
eterious effects of the biopharmaceuticals on the health of these animals. Through selective 
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promoters for the mammary gland, such as αs1-casein (Platenburg et al., 1994; Zinovieva et al., 
1998) and whey acid protein - WAP (Devinoy et al., 1994; Rokkones et al., 1995), gene expres-
sion can be targeted to the mammary gland, with the release of the desired protein in the milk.
The purification of recombinant protein in milk is generally not a problem. Milk does 
not contain large amounts of proteases and the casein can be removed easily, without aggres-
sive procedures. A chromatograph can, in most cases, eliminate most unwanted proteins, leav-
ing the target protein with a high level of purity. However, it should be considered that milk 
is a biological complex with many components, and complete purification in some cases can 
be very difficult. The biosecurity of the biopharmaceuticals thus obtained can be assured by 
means of sanitary control of livestock, especially animals free of contamination with prions.
Many animal species have been used as bioreactors, including mice, cattle, pigs, 
goats, sheep, and rabbits. The transgenesis of production animals is still in development; some 
important steps have been taken, but this still requires the development of stronger promoters 
to ensure adequate efficiency, thus reducing transgenesis costs and enabling this procedure 
to be carried out on an industrial scale. With the new technologies of manipulation of bovine 
embryos, commercial cloning and the sequencing of the bovine genome, production of these 
genetically modified animals is the next step. In a few years, genetic improvement of these 
animals will be attained at a much faster rate than is possible today, enabling the production 
of animal-origin foods with elevated nutritional properties, more resistance to decomposition 
and with better organoleptic characteristics.
BIOSECURITY IN OBTAINING AND REARING GENETICALLY MODIFIED 
ANIMALS
According to Brazilian legislation concerning genetically modified organisms, the Bi-
osecurity Law (law 11105 of March 24, 2005 and Decree No. 5.591 of November 22, 2005), 
to develop, create or use a genetically modified animal, the animal facility and laboratory must 
have a Certificate of Quality in Biosecurity, or CQB, which is awarded by the National Technical 
Commission on Biosecurity (CTNBio) of the Ministry of Science and Technology. The institu-
tion must also appoint an Internal Biosecurity Commission (CIBio) to manage activities involv-
ing genetically modified organisms. The laboratories should be equipped for biosecurity at a 
level equivalent to the risk class of the genes or agents with which it will work, and the staff must 
be trained and educated to adequately carry out genetic modifications. The disposal of materials 
is extremely important; this material must be inactivated prior to disposal in the environment.
Various forms of inactivation of genes and/or vectors can be found, but the autoclave 
is one of the most secure and widely used. The animal facility should also possess some spe-
cific features to accommodate the genetically modified animals. The animals must be kept in 
separate, locked rooms, the doors of which must bear the biosecurity symbol and information 
on which animals are kept there. Animals should be housed in cages for easy cleaning and 
decontamination, which should be well sealed to prevent the escape of animals or the entry 
of other animals into the cage. Ventilated shelving or racks, or microisolators, are suitable for 
the maintenance of genetically modified animals. After euthanasia, the corpses of genetically 
modified animals should be sent for incineration along with medical waste. All accidents (e.g., 
escape of animals, spill of liquids originating from genetically modified animals) must be re-
ported to the CIBio of the unit, which in turn should report them to CTNBio.
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Most genetically modified animals belong to risk class 1 and thus can be produced and 
reared in laboratories or animal facilities that are biosecurity level 1. It is always important 
to remember that all rules of bioethics applicable to conventional laboratory animals (such as 
methods of euthanasia and attitudes that prevent the suffering of animals) should also be ap-
plied to genetically modified animals.
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